James Case, MD
Endocrinology, Diabetes & Metabolism · Orange, CTNPI 1750866182
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,370 of the $35,978 with a category attached, or 90.0%. GE HealthCare accounts for 93.6% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $35,343, more than ten times the $62 reported in 2022. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $408.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$34K
- Amgen$673
- Boehringer Ingelheim$230
- Ascendis Pharma Endocrinology Inc$176
- Johnson & Johnson$130
- Novo Nordisk$129
- plus $958 from 18 others
What the payments were for
- Consulting fees$32,37090%
- Travel & lodging$1,3114%
- Food & beverage$2,2976%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 10 | $33,681 |
| Amgen | 16 | $673 |
| Boehringer Ingelheim | 6 | $230 |
| Ascendis Pharma Endocrinology Inc | 6 | $176 |
| Johnson & Johnson | 1 | $130 |
| Novo Nordisk | 5 | $129 |
| Lilly USA, LLC | 5 | $109 |
| Recordati_rare_diseases_inc. | 4 | $100 |
| Insulet Corporation | 5 | $93 |
| Kyowa Kirin, Inc. | 4 | $81 |
| AstraZeneca | 3 | $78 |
| Radius Health, Inc. | 4 | $75 |
| Tandem Diabetes Care, Inc. | 2 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Medtronic | 3 | $55 |
| Dexcom, Inc. | 2 | $41 |
| Intra-sana Laboratories | 2 | $40 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Abbott | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,978 in reported general payments places this provider in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $30,511 |
| JardianceEmpagliflozin | 34 | $27,118 |
| MounjaroTirzepatide | 16 | $25,713 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,556 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 13 | $798 |
| Levothyroxine Sodium | 33 | $415 |
| Metformin Hcl ErMetformin Hcl | 19 | $347 |
| Metformin Hcl | 21 | $221 |
| Atorvastatin Calcium | 28 | $203 |
| Alendronate Sodium | 16 | $141 |
| Methimazole | 12 | $131 |
| Glimepiride | 24 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $129 | $30,51127 claims |
| Boehringer IngelheimJardiance | $230 | $27,11834 claims |
| Lilly USA, LLCMounjaro | $109 | $25,71316 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $41533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Orange
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
- Glenn RichTrumbull$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.